As detailed in the Methods section, this composite biomarker was derived from an integrated analysis of 82 treatment-naïve SCLC single-cell transcriptomes and a systematic review of six PARP-ICB phase II trials (67). This evidence concerns the gene PARP1 and small cell lung carcinoma.